This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, P. Articles by Lee, Y.-S. Search for Related Content PubMed PubMed Citation Articles by Chan, P. Articles by Lee, Y.-S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cholesterol High Blood Pressure

(Hypertension. 1996;28:647-651.)
© 1996 American Heart Association, Inc.

Articles

Beneficial Effects of Pravastatin on Fasting Hyperinsulinemia in Elderly Hypertensive Hypercholesterolemic Subjects

Paul Chan; Brian Tomlinson; Ching-Bing Lee; Wen-Harn Pan; Ying-Shiung Lee

the Clinical Pharmacology and Therapeutics Unit, Department of Cardiology (P.C.); Taipei Municipal Chung-Hsiao Hospital and Institute of Clinical Medicine (P.C.) of the National Yang-Ming University and Division of Cardiology (C.-B.L., Y.-S.L.); Chang-Gung Medical Center at Linkou and Institute of Biomedical Sciences (W.-H.P.), Academia Sinica, Taipei, Taiwan; and Department of Clinical Pharmacology (B.T.), Chinese University of Hong Kong.

We undertook this prospective double-blind, placebo-controlled study to evaluate the efficacy and safety of low-dose (15 mg) pravastatin in elderly hypercholesterolemic hypertensive subjects with concurrent antihypertensive treatment and to determine whether fasting hyperinsulinemia could also be improved. At three hypertension and lipid clinics of two medical centers, 96 elderly (49 women, 47 men) ambulatory subjects were randomized to active treatment or placebo for 12 months after a 3-month single-blind lead-in period. Hypertensive subjects with plasma total cholesterol levels of at least 6.47 mmol/L (250 mg/dL) and triglyceride levels less than 3.39 mmol/L (300 mg/dL) were treated with 15 mg pravastatin for 12 months after receiving 3 months of the American Heart Association step I diet. Lipid, glucose, and fasting insulin levels were measured; clinical laboratory tests included liver function and creatine kinase determinations. After 12 months of pravastatin therapy, plasma total cholesterol concentration decreased by 25.1% (from a mean of 7.29 to 5.47 mmol/L, P<.05), low-density lipoprotein cholesterol decreased by 30.2% (from 5.27 to 3.68 mmol/L, P<.05), and triglycerides decreased by 10.7% (from 1.68 to 1.50 mmol/L, P<.05). High-density lipoprotein cholesterol increased by 9.2% (from 1.20 to 1.31 mmol/L, P<.05). Fasting insulin levels decreased from 89.0 to 61.5 pmol/L (P<.05). All of these changes were greater (P<.05) than any tendency toward change in the placebo group. Adverse events and clinical laboratory abnormalities were generally mild and transient in both placebo and pravastatin groups. Study drugs were withdrawn from one subject in each group with asymptomatic creatine kinase elevations. We conclude that low-dose pravastatin was effective and safe in the treatment of hypercholesterolemic hypertensive subjects on concurrent antihypertensive therapy. It also improved fasting hyperinsulinemia despite the use of ß-blockers and diuretics in these hypertensive subjects.

Key Words: cholesterol • hydroxymethylglutaryl CoA reductases • hyperinsulinism • pravastatin

This article has been cited by other articles:

				C. G. P. Roberts, E. Guallar, and A. Rodriguez Efficacy and Safety of Statin Monotherapy in Older Adults: A Meta-Analysis J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2007; 62(8): 879 - 887. [Abstract] [Full Text] [PDF]

				S. D. Ross, I. E. Allen, J. E. Connelly, B. M. Korenblat, M. E. Smith, D. Bishop, and D. Luo Clinical Outcomes in Statin Treatment Trials: A Meta-analysis Arch Intern Med, August 9, 1999; 159(15): 1793 - 1802. [Abstract] [Full Text] [PDF]